treatment

First Lady Anna Stein, NCDHHS and Morse Clinics Celebrate First Mobile Opioid Treatment Program Unit in North Carolina

Raleigh, NC, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Credentialed media are invited to attend the unveiling of the first Mobile…

4 months ago

Testosterone Booster for Muscle Gain: Men Opt for OTC Supplement Form Natural Testosterone Replacement Therapy (TRT) Treatment in 2025

New York City, NY, July 27, 2025 (GLOBE NEWSWIRE) -- A recent survey shows that TestoPrime is widely regarded by…

4 months ago

Press Release: Sanofis Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase…

4 months ago

EURneffy approved as the first needle-free anaphylaxis treatment of adults and children in the UK

Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has…

5 months ago

Johnson & Johnson Launches VARIPULSE Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment

The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system,…

5 months ago

Sirtex Medical’s SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma…

5 months ago

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…

5 months ago

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

July 07, 2025 08:00 ET  | Source: KALA BIO, Inc. ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO,…

5 months ago

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with…

5 months ago

ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment

LONDON, June 28, 2025 /PRNewswire/ -- A team of international scientists has made a major leap forward in diabetes research…

5 months ago